🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

mCSPC front line drugs: Abiraterone(generic)-$2,800/month [2 yrs - $67,200] Enzalutamide - [2 yrs - ~$240,000] Docetaxel x 6 cycles - ~$27,000 #FinancialToxicity ⁦The ASCO Post ⁦Christopher Sweeney, MBBS⁩ ⁦Nick James also on @Prof-Nick-James.bsky.social⁩ ⁦⁦Brian F. Chapin⁩ nejm.org/doi/full/10.10…

We present #RC_pentafecta as a standardizable composite endpoint that incorporates peri-operative morbidity and oncologic adequacy as a potential tool to assess the quality of radical cystectomy BJU International USC Urology USC doi.org/10.1111/bju.14…

Dusting had a significantly shorter operation time, whilst the fragmentation technique had a significantly better stone-free rate. Both techniques have comparable safety, hospital stay and requirement for secondary procedures. buff.ly/2ymuNhZ

A practice-changing clinical trial: the ARCHES. buff.ly/313ujtt Enzalutamide with ADT significantly reduced the risk of metastatic progression or death over time versus placebo plus ADT in men with metastatic hormone-sensitive PCa #ProstateCancer #arches #Enzalutamide

Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019 buff.ly/2SM42wP

‼️“Hey, let me Google it!”. How much familiar is to you this scenario? Check out our paper in European Urology Oncology doi.org/10.1016/j.euo.… we aimed to assess the interest of the worldwide population in PCa treatments European Association of Urology (EAU) European Society of Residents in Urology #urosome

6 criteria could serve as a benchmark for assessing the wave of novel bladder-sparing therapies that are entering the BCG-unresponsive NMIBC space -they should be easier and better tolerated than cystectomy, while not resulting in worse oncologic outcomes. futuremedicine.com/doi/10.2217/im…

Adjuvant radiotherapy following radical prostatectomy prolongs biochemical recurrence-free survival compared with radical prostatectomy alone in patients with positive margins or extracapsular extension.

Intravesical instillation of botulinum toxin A and low-energy shockwaves in pts with refractory OAB is safe and effective for 2 mons.The effect is not durable due to the inadequacy of the dose of botulinum and/or non-optimised shockwave technique. tandfonline.com/doi/full/10.10…

"The high volume and contradictory nature of medical research findings is not only because of publication bias. A more fundamental problem is the widespread misunderstanding of the nature of statistical significance". An old but still interesting topic! buff.ly/2YUo9zh

We have to start using this European Association of Urology (EAU) BCR risk stratification in daily practice. Really useful #apccc19 Derya Tilki, MD

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? euoncology.europeanurology.com/article/S2588-…

How to treat men with newly diagnosed cN1 cM0 #ProstateCancer. Nick James also on @Prof-Nick-James.bsky.social Uni of Birmingham discussed systemic therapy options for men w/ node-positive HSPC @apccc19. Written highlights by Hanan Goldberg Upstate Medical University on UroToday. bit.ly/34ctfpt #APCCC19

Read the UPDATED Amer. Urol. Assn. Guidelines for #BPH #13 TURP can be done monopolar, bipolar or 120W PVP ow.ly/tGKk50vY6Dp

The Finnish Randomized Trial of Adjuvant Radiotherapy Versus Observation After Prostatectomy: Almost a Trial of Adjuvant Versus Late Salvage Radiotherapy buff.ly/2lNU2Hk Daniel E Spratt

Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer Uromigos Andrea Necchi europeanurology.com/article/S0302-…

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees † academic.oup.com/annonc/advance…

December Issue: Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment Christian Gratzke @ProfCRChapple buff.ly/2zPJhIg

The journal has been upgraded from Q3 in 2018 to Q2 in 2019 according to SJR with a cite score (2 years) of 2.10. scimagojr.com/journalrank.ph… 🎉🎉🎉

Drug-delivering devices in the urinary tract: A systematic review tandfonline.com/doi/full/10.10…